Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)

This study has been terminated.
(for efficacy and safety reasons)
Sponsor:
Collaborators:
Rhode Island Hospital
Memorial Hospital of Rhode Island
Information provided by (Responsible Party):
howard safran, Brown University
ClinicalTrials.gov Identifier:
NCT00787852
First received: November 7, 2008
Last updated: July 24, 2014
Last verified: July 2014
  Purpose

The purpose of this study is to evaluate if a maximum dose of 100 mg of dasatinib with concurrent chemoradiation can be tolerated in patients with chemotherapy naive stage III NSCLC in separate cohorts of locally advanced and potentially resectable disease.


Condition Intervention Phase
Non-Small Cell Lung Cancer
Drug: Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47
Drug: Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Study of Dasatinib With Concurrent Chemoradiation for Stage III NSCLC Principal Investigator: Howard Safran, MD.

Resource links provided by NLM:


Further study details as provided by Brown University:

Primary Outcome Measures:
  • Number of Patients Who Came Off Study for Toxicity Using CTC Version 3.0 [ Time Frame: within 28 days after the last radiation treatment ] [ Designated as safety issue: Yes ]
    6 patients came off study for toxicity


Secondary Outcome Measures:
  • Complete and Partial Response by CT Scan or MRI [ Time Frame: within 30 days of last treatment ] [ Designated as safety issue: No ]

Enrollment: 11
Study Start Date: March 2009
Study Completion Date: December 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group 1: Radiation, Paclitaxel, Carbo, Dasatinib days 1-47

Locally Advanced Stage III NSCLC DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib & Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43

Dasatinib is to be taken 1x daily

  1. 50 mg daily 100 mg daily
  2. 70 mg daily 100 mg daily
  3. 100 mg daily 100 mg daily

Maintenance x 2 years*

Drug: Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47

Locally Advanced Stage III NSCLC DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib & Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43

Dasatinib is to be taken 1x daily

  1. 50 mg daily 100 mg daily
  2. 70 mg daily 100 mg daily
  3. 100 mg daily 100 mg daily

Maintenance x 2 years*

Other Name: Group 1: Locally Advanced Stage III NSCLC
Experimental: Group 2: Radiation, Paclitaxel, carbo, Dasatinib days 1-38

Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC SCHEMA DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-38 Paclitaxel 1 8 15 22 29 36 Surgery Carboplatin 1 8 15 22 29 36 Dasatinib & Maintenance Dasatinib RT: External radiotherapy 50.4 Gy, 1.8 Gy/fx for 28 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36

Dasatinib is to be taken 1x daily

  1. 50 mg daily 100 mg daily
  2. 70 mg daily 100 mg daily
  3. 100 mg daily 100 mg daily Maintenance x 2 years*
Drug: Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38

Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC SCHEMA DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-38 Paclitaxel 1 8 15 22 29 36 Surgery Carboplatin 1 8 15 22 29 36 Dasatinib & Maintenance Dasatinib RT: External radiotherapy 50.4 Gy, 1.8 Gy/fx for 28 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36

Dasatinib is to be taken 1x daily

  1. 50 mg daily 100 mg daily
  2. 70 mg daily 100 mg daily
  3. 100 mg daily 100 mg daily Maintenance x 2 years*
Other Name: Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC

Detailed Description:

Describe the safety of maintenance dasatinib, 100 mg/day for 2 years, in patients with stage III NSCLC.

For patients with potentially resectable disease, to assess the pathologic complete response following neoadjuvant dasatinib, paclitaxel, carboplatin and 50.4 Gy concurrent radiation.

For patients with locally unresectable disease, to obtain radiographic response data following dasatinib, paclitaxel, carboplatin and 64.8 Gy radiation.

  Eligibility

Ages Eligible for Study:   19 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pathologically proven (either histologic or cytologic) diagnosis of Stage IIIA or IIIB non-small cell lung cancer; excluding patients with N3 disease based on supraclavicular or contralateral hilar adenopathy, [according to AJCC Staging, 6th edition; see Appendix G] within 4 weeks of registration.
  • No prior chemotherapy or radiation for lung cancer. No prior radiation for any malignancy within the radiation field.
  • Patients may be potentially resectable or unresectable.
  • Stage III A or B disease, including no distant metastases- based on following diagnostic workup:

    • History/physical examination prior to registration.
    • CT Scan of the chest or Pet Scan within 28 days of study entry.
    • CT Scan of abdomen or MRI of abdomen or Pet Scan within 28 days of study entry.
    • An MRI of the brain or Head CT Scan with contrast within 28 days of study entry.
    • Total body PET scan within 6 weeks of study entry is highly recommended and required for operable patients. If a PET scan is performed then a bone scan is not required.
    • A bone scan should be performed within 6 weeks of study entry. A bone scan is not needed if a PET scan is performed.
    • Mediastinoscopies are highly recommended. Mediastinoscopy is required for all patients not undergoing PET scans and for those who are operable.
  • Patients must have measurable or evaluable disease.
  • Patients with post-obstructive pneumonia are eligible.
  • Patients must be at least 3 weeks from prior thoracotomy (if performed)
  • ECOG Performance Status 0-1. Age > 18.
  • Post-op predicted FEV1 > 40% to be eligible for surgical resection.
  • CBC/differential obtained within 2 weeks prior to registration on study, with adequate bone marrow function defined as follows:

    • Absolute neutrophil count (ANC) > 1,500 cells/ul.
    • Platelets > 100,000 cells/ul.
    • Hemoglobin > 9.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb > g/dl is acceptable.)
    • PT, PTT all Grade 0-1
    • Serum creatinine < 1.5 x ULN
    • Total bilirubin < 2.0 times the institutional Upper Limit of Normal (ULN)
    • AST and ALT < 2.5 x the ULN
    • Serum Na, K+, Mg2+, Phosphate in normal range (LLN)
    • Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 72 hours prior to the start of study drug administration.
  • Persons of reproductive potential must agree to use and utilize an adequate method of contraception throughout treatment and for at least 4 weeks after study drug is stopped prior to study enrollment, women of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy.
  • If you are capable of giving birth to or fathering a child, you must agree to use a form of birth control (examples of effective birth control are: a condom or a diaphragm with spermicidal jelly; oral, injectable, or implanted birth control; or abstinence) that is medically acceptable to your study doctor while taking part in this research study. This is necessary because the treatment involved in this study may be significantly teratogenic.
  • PFT's within 8 weeks of study entry
  • EKG within 6 weeks of study entry
  • Ability to take oral medication (dasatinib must be swallowed whole)
  • Patient must sign study specific informed consent prior to study entry.
  • Patient agrees to discontinue St. Johns Wort while receiving dasatinib therapy (discontinue St. Johns Wort at least 5 days before starting dasatinib)

Exclusion Criteria:

  • Supraclavicular disease
  • Pleural or pericardial effusion of any grade
  • No prior malignancy [other than the one treated in this study] which required radiotherapy or systemic treatment within the past 3 years
  • Severe, active co-morbidity, defined as follows:
  • Cardiac Symptoms; any of the following should be considered for exclusion:

    • Uncontrolled angina, congestive heart failure or MI within (6 months)
    • Diagnosed congenital long QT syndrome
    • Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)
    • Prolonged QTc interval on pre-entry electrocardiogram (> 450 msec)
    • Subjects with hypokalemia or hypomagnesemia if it cannot be corrected prior to dasatinib administration
    • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
    • Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive.
    • Protocol-specific requirements may also exclude immuno-compromised patients
    • History of significant bleeding disorder unrelated to cancer, including:
    • Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease).
    • Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies).
    • Ongoing or recent (< 3 months) significant gastrointestinal bleeding
    • Concomitant Medications, any of the following should be considered for exclusion:

      • Category I drugs that are generally accepted to have a risk of causing Torsades de Pointes including: (Patients must discontinue drug 7 days prior to starting dasatinib):

        1. quinidine, procainamide, disopyramide
        2. amiodarone, sotalol, ibutilide, dofetilide
        3. erythromycin, clarithromycin
        4. chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide, cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine
  • Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious) illness

    • Women who:are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 4 weeks after cessation of study drug, or have a positive pregnancy test at baseline, or are pregnant or breastfeeding
  • Any history of allergic reaction to paclitaxel or other taxanes, or to carboplatin.

    • Uncontrolled neuropathy grade 2 or greater regardless of cause.
    • Patients who are on full dose aspirin, Clopidogrel bisulfate (plavix) or other GPIIb/IIIa platelet inhibitors are not eligible. Patients must have these agents stopped within 7 days of initiated treatment. Patients may be on low dose aspirin (81 mg/day).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00787852

Locations
United States, Rhode Island
Lifespan Hospitals
Providence, Rhode Island, United States, 02906
Sponsors and Collaborators
Brown University
Rhode Island Hospital
Memorial Hospital of Rhode Island
Investigators
Study Director: Howard Safran, md Brown University
  More Information

No publications provided

Responsible Party: howard safran, Principal Investigator, Brown University
ClinicalTrials.gov Identifier: NCT00787852     History of Changes
Other Study ID Numbers: BrUOG-NSCL-216
Study First Received: November 7, 2008
Results First Received: July 22, 2013
Last Updated: July 24, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Brown University:
dasatinib
radiation
paclitaxel
carboplatin
NSCLC
safety addition of dasatinib to chemo RT stage III NSCLC

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Carboplatin
Dasatinib
Paclitaxel
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Enzyme Inhibitors
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Tubulin Modulators

ClinicalTrials.gov processed this record on November 24, 2014